Concord Biotech Q4 FY26 Earnings Call — Analysis (NSE: CONCORDBIO)
Concord Biotech reports a challenging FY26 with 12% revenue decline, but guides for strong FY27 recovery surpassing historical 18% growth, backed by H1 visibility and multiple growth levers.
The take
Q4FY26 API Revenue ₹264 Cr ( -27% YoY ) . New guidance — FY27 company revenue growth slightly better than historical 18% . New story: New product and market expansion .
Results
Q4FY26 revenue ₹325.89 Cr, -24% YoY; API revenue ₹264 Cr (-27% YoY), formulations declined 8%; FY26 EBITDA ₹367 Cr (margin 35%, adjusted 39%); PAT ₹260 Cr (-30% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Revenue Growth (Q4) | -24% | yoy · Q4FY26 | |
| API Revenue | ₹264 Cr | -27% | yoy · Q4FY26 |
| Formulations Revenue Growth (Q4) | -8% | yoy · Q4FY26 | |
| Total Revenue Growth (FY26) | -12% | yoy · FY26 | |
| EBITDA | ₹367 Cr | point_in_time · FY26 · FY26 | |
| EBITDA Margin | 35% | point_in_time · FY26 · FY26 reported | |
| Adjusted EBITDA Margin | 39% | none · FY26 · excludes new formulation & US subsidiary expenses | |
| PAT | ₹260 Cr | -30% | yoy · FY26 |
| Cash & Equivalents | ₹414 Cr | point_in_time · Mar-26 · as on 31 Mar 2026 | |
| Capex | ₹65 Cr | point_in_time · FY26 · FY26 | |
| Cash Flow from Operations | ₹267 Cr | point_in_time · FY26 · 73% CFO/EBITDA conversion |
Guidance
FY27 revenue growth expected to be slightly better than historical ~18%, with strong H1 visibility; no explicit EBITDA guidance but 1–1.5% margin uplift from renewable energy and operating leverage.
What management committed to
- [Concord Biotech] expects FY27 revenue growth to be slightly better than [its] historical growth of about 18%, with strong visibility in the first half. — slightly better than historical 18%, FY27
- [Concord Biotech] expects renewable energy (solar) to contribute 1–1.5% positive impact on EBITDA margin in FY27. — 1% to 1.5%, FY27
- [Concord Biotech] expects maintenance capex in FY27 to be ₹20-30 Cr, with no major capacity expansion unless a new customer project requires it. — ₹20-30 Cr, FY27
- CDMO (contract development and manufacturing for innovators) revenue is expected to account for 1–4% of [Concord Biotech]'s API revenue in FY27, with potential upside from an advanced-stage deal. — 1-4%, FY27
- [Concord Biotech]'s US subsidiary Stellon Biotech will commence supplies in the first half of FY27. — first half of the year, H1FY27
- [Concord Biotech] expects elevated inventory days (480 days as of Mar-26) to normalize to historical levels in H1FY27 as staggered shipments are executed. — normalize, H1FY27
Key themes
Navigating transient headwinds, positioning for growth
How the narrative shifted
- Recovery from transient headwinds: Management frames FY26 challenges (geopolitical, regulatory, supply-chain) as temporary and non-structural, positioning FY27 as a year of normalized performance.
- New product and market expansion: Nystatin, Fusidic Acid, CDMO deals, and injectables are the key volume drivers; management highlights progress in customer acquisition and limited competition.
- Operating leverage and margin recovery: With full costs of injectables and Stellon already booked in FY26, any incremental revenue should flow through to EBITDA; energy savings add 1-1.5% margin tailwind.
- Geopolitical uncertainty in Middle East: War-related disruptions have delayed tenders and formulations supply; management sees gradual improvement via API, but cannot provide timeline for resolution.
- Capacity headroom and capital discipline: Existing manufacturing base supports ₹3,000 Cr peak revenue with low maintenance capex; no large capex needed for 4-5 years, enabling cash generation and optionality.
- US market entry via Stellon: Stellon Biotech, the US subsidiary, is a vehicle for direct marketing and distribution; supplies to start in H1FY27, opening a new geography for own-brand formulations.
Operational commentary
- Injectable facility (Unit 4) received WHO-GMP certification, commenced supplies to emerging markets (Southeast Asia, Africa), customer audits underway; revenue contribution still ramping.
- Soft gel facility commercialized, creating additional revenue stream.
- US subsidiary Stellon Biotech incorporated; direct marketing of Concord products in US expected to start supplies in H1FY27.
- Supplies of APIs to two innovator companies commenced; Nystatin customer acquisitions progressing; Fusidic Acid commercialized with limited competition from Europe.
- CDMO discussions in advanced stages; at least one large deal may close soon, could lift CDMO revenue from current single-digit share.
- Capacity utilization: Unit 1 at 77%, Unit 2 at 30%, Unit 3 at 53%; existing capacities can support peak revenue of ~₹3,000 Cr.
- Cleared multiple regulatory inspections (US FDA, EU GMP, Russia GMP, NAFDAC, WHO-GMP) across facilities, reinforcing global compliance.
- Investment in Celliimune Biotech for cell & gene therapy platform.
- Middle East tender (~₹25 Cr) and US Veterans Affairs tender (~₹25 Cr) remain in abeyance due to geopolitical/ war conditions; gradual recovery via API supplies seen.
- Customers shifted from bulk to staggered quarterly procurement, smoothing revenue distribution but causing temporary inventory build-up.
Analyst Q&A
Q. Do we have visibility in first half to start the growth phase; can we expect growth better than historical 18-20%?
We have a very good amount of visibility in the first half; expect growth to be slightly better than historical 18% in FY27, starting from Q1/Q2.
Q. What was the sales exposure to Middle East and the size of the tender that was not finalized?
Tender impact was ~₹25 Cr for formulations; total Middle East exposure around ₹50 Cr; tender remains in abeyance, but API supplies are gradually resuming.
Q. Can you give a breakup of volume vs pricing growth for API in FY26?
There was no price growth; all movement was volume-driven; volumes declined in FY26. No major pricing pressure expected going forward.
Q. When do you expect the US Veterans Affairs tender issue to get resolved?
It depends on the war situation; nobody has clarity. Some shift from formulations to API is occurring as an alternative strategy, but no timeline can be given.
Q. Could margin improvement be 200bps or more due to energy savings and reduced losses in new ventures?
Possibly yes: 1–1.5% from power, plus ~50bps from operating leverage on Stellon/injectables. Full losses were ₹38 Cr injectable +₹10 Cr Stellon; exact reduction is early to say.
Q. Do you have an EBITDA margin guidance for FY27?
We have not given a specific margin guidance; only indicated positive levers (power savings, operating leverage) but no number.
Q. Is there any risk of inventory write-off given the sharp increase in inventory days to 480?
From a formulation standpoint, no risk of write-off because production is order-based. The elevated inventory is mainly API, linked to customer demand and will moderate in H1.
Research and educational content only. Not investment advice.